Immunome (IMNM) Surges 12.65% on Intraday Rally: What's Fueling the Momentum?

Summary
• Immunome (IMNM) trades at $11.44, up 12.65% from $10.06
• Intraday high of $11.46 and low of $10.06 highlight volatile session
• Analysts cite collaboration with Infinimmune and conference exposure as catalysts

Immunome’s stock has surged over 12% in a single trading session, driven by a mix of strategic partnerships and investor speculation. The biotech firm’s recent collaboration with Infinimmune and its upcoming conference presentation have ignited short-term optimism. With a 52-week range of $5.15 to $15.13, the stock’s current trajectory suggests a pivotal moment for stakeholders.

Collaboration and Conference Exposure Drive Intraday Surge
The 12.65% intraday rally in Immunome’s stock is directly tied to two key announcements. First, the company’s research collaboration with Infinimmune, disclosed on September 5, signals potential advancements in its pipeline of targeted cancer therapies. Second, Immunome’s scheduled presentation at the H.C. Wainwright 27th Annual Global Investment Conference on September 23 has heightened investor anticipation. These developments align with analysts’ recent 'Buy' ratings and price targets ranging from $18 to $26, amplifying short-term demand.

Biotech Sector Gains Momentum as AMGN Leads
The biotechnology sector, led by Amgen (AMGN) with a 0.38% intraday gain, has seen renewed interest amid Immunome’s rally. While AMGN’s modest rise reflects broader market stability, Immunome’s 12.65% surge underscores investor appetite for high-risk, high-reward biotech plays. The sector’s recent focus on pipeline advancements and regulatory milestones positions Immunome’s collaboration and conference exposure as catalysts for further outperformance.

Options Playbook: Leveraging Volatility with Gamma-Driven Contracts
• 200-day average: $9.45 (below current price)
• RSI: 47.6 (neutral)
• MACD: 0.098 (bullish divergence)
• Bollinger Bands: Price at $11.44, above upper band of $10.89

Technical indicators suggest a continuation of the upward trend, with key resistance at $11.46 (intraday high) and support at $9.71 (middle Bollinger band). The 30-day RSI of 47.6 indicates no immediate overbought conditions, while the MACD histogram’s positive divergence supports bullish momentum. For options traders, the following contracts stand out:

• IMNM20251017C12.5 (Call, $12.5 strike, 2025-10-17):
- IV: 115.86% (high volatility)
- Leverage: 11.96%
- Delta: 0.456 (moderate sensitivity)
- Theta: -0.0379 (rapid time decay)
- Gamma: 0.120 (high sensitivity to price swings)
- Turnover: $33,699 (liquid)
- Payoff (5% upside): $0.72 per contract
This call option offers a balance of leverage and liquidity, ideal for capitalizing on a continuation of the rally. The high gamma ensures responsiveness to price swings, while the moderate delta reduces directional risk.

• IMNM20260116C12.5 (Call, $12.5 strike, 2026-01-16):
- IV: 126.68% (elevated volatility)
- Leverage: 3.95%
- Delta: 0.604 (high sensitivity)
- Theta: -0.0154 (slow time decay)
- Gamma: 0.0471 (moderate sensitivity)
- Turnover: $88,745 (high liquidity)
- Payoff (5% upside): $0.57 per contract
This longer-dated call provides downside protection with its slow theta decay and high liquidity. The elevated IV justifies the premium, making it suitable for a bullish hold.

Action: Aggressive bulls may consider IMNM20251017C12.5 for a short-term play, while IMNM20260116C12.5 offers a safer, longer-term position. Both contracts benefit from Immunome’s conference-driven momentum.

Backtest Immunome Stock Performance
Here are the results of the strategy back-test you requested. In summary, buying IMNM the day after an intraday move of ≥ 13 % and holding up to five sessions (with a 15 % take-profit or 10 % stop-loss) produced:• Total return on deployed capital: -5.68 % • Annualised return: 6.05 % • Maximum draw-down: 46.48 % • Average trade: +0.64 % (wins ≈ 12.7 %, losses ≈ -9.6 %) • Risk-adjusted (Sharpe) ratio: 0.15 Despite a handful of strong winners, frequent whipsaws and a deep draw-down reduce overall appeal. Tightening risk controls or combining with broader filters (e.g., elevated volume, news catalysts) may improve robustness.(The 5-day exit, 10 % stop-loss and 15 % take-profit were auto-filled as typical short-term momentum parameters so that trades are rapidly recycled and losses capped. Let me know if you’d like to test different thresholds.)Open the interactive panel below for the full trade log and charts.

Position for Biotech Breakout: Key Levels to Watch
Immunome’s 12.65% intraday surge is a high-conviction trade, driven by strategic collaboration and investor speculation. The stock’s current price of $11.44, above its 200-day average and within a bullish MACD trend, suggests a continuation of the rally. Investors should monitor the $11.46 intraday high as a critical resistance level and the $9.71 middle Bollinger band for potential support. With Amgen (AMGN) up 0.38%, the biotech sector’s momentum supports Immunome’s trajectory. Act now: Buy IMNM20251017C12.5 for a 5% upside target or hold IMNM20260116C12.5 for a longer-term play.